Aytu BioPharma, Inc. (AYTU)
USD 1.02
(-0.25%)
USD 1.02
(-0.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -15.84 Million USD | 7.07% |
| 2023 | -17.05 Million USD | 84.33% |
| 2022 | -108.78 Million USD | -86.62% |
| 2021 | -58.29 Million USD | -327.97% |
| 2020 | -13.62 Million USD | 71.12% |
| 2019 | -47.16 Million USD | -362.97% |
| 2018 | -10.18 Million USD | 54.74% |
| 2017 | -22.5 Million USD | 20.13% |
| 2016 | -28.18 Million USD | -264.87% |
| 2015 | -7.72 Million USD | -38.44% |
| 2014 | -5.57 Million USD | -9632.88% |
| 2013 | -57.31 Thousand USD | 3.95% |
| 2012 | -59.67 Thousand USD | 56.38% |
| 2011 | -136.8 Thousand USD | -126.98% |
| 2010 | -60.27 Thousand USD | -2.34% |
| 2009 | -58.89 Thousand USD | -3.01% |
| 2008 | -57.17 Thousand USD | -16.79% |
| 2007 | -48.95 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -2.89 Million USD | -1213.64% |
| 2024 Q1 | -8.12 Million USD | -230.08% |
| 2024 Q4 | -4.62 Million USD | -59.76% |
| 2024 Q2 | -220 Thousand USD | 97.29% |
| 2023 Q4 | -2.46 Million USD | 65.83% |
| 2023 Q3 | -7.2 Million USD | -7.62% |
| 2023 FY | -17.05 Million USD | 84.52% |
| 2023 Q1 | -700 Thousand USD | 95.65% |
| 2023 Q2 | -6.69 Million USD | -855.71% |
| 2022 Q3 | -53.29 Million USD | -361.39% |
| 2022 Q4 | -16.09 Million USD | 69.81% |
| 2022 FY | -110.17 Million USD | -89.01% |
| 2022 Q2 | -11.55 Million USD | 58.53% |
| 2022 Q1 | -27.85 Million USD | -46.58% |
| 2021 Q1 | -4.31 Million USD | -36.83% |
| 2021 Q4 | -19 Million USD | 25.37% |
| 2021 Q2 | -9.53 Million USD | -121.11% |
| 2021 Q3 | -25.46 Million USD | -167.16% |
| 2021 FY | -58.28 Million USD | -1475.55% |
| 2020 Q4 | -3.15 Million USD | 40.9% |
| 2020 FY | -3.69 Million USD | 92.16% |
| 2020 Q3 | -5.33 Million USD | -2438.1% |
| 2020 Q1 | -4.92 Million USD | 66.08% |
| 2020 Q2 | -210 Thousand USD | 95.74% |
| 2019 Q2 | -4.65 Million USD | -35.14% |
| 2019 Q1 | -3.44 Million USD | -729.42% |
| 2019 Q4 | -14.53 Million USD | -223.23% |
| 2019 FY | -47.16 Million USD | -362.97% |
| 2019 Q3 | -4.49 Million USD | 3.47% |
| 2018 Q1 | -4.24 Million USD | -39.64% |
| 2018 FY | -10.18 Million USD | 54.74% |
| 2018 Q4 | 547.56 Thousand USD | 119.43% |
| 2018 Q3 | -2.81 Million USD | 23.28% |
| 2018 Q2 | -3.67 Million USD | 13.48% |
| 2017 Q3 | -5.21 Million USD | -8.29% |
| 2017 Q2 | -4.81 Million USD | 15.85% |
| 2017 Q4 | -3.03 Million USD | 41.72% |
| 2017 FY | -22.5 Million USD | 20.13% |
| 2017 Q1 | -5.72 Million USD | 62.58% |
| 2016 Q3 | -7.27 Million USD | -118.28% |
| 2016 Q4 | -15.29 Million USD | -110.3% |
| 2016 Q1 | -2.27 Million USD | -5.6% |
| 2016 Q2 | -3.33 Million USD | -46.4% |
| 2016 FY | -28.18 Million USD | -264.87% |
| 2015 Q1 | -11.19 Thousand USD | 5.31% |
| 2015 Q4 | -2.15 Million USD | -17.0% |
| 2015 Q3 | -1.84 Million USD | -11593.47% |
| 2015 Q2 | -15.75 Thousand USD | -40.71% |
| 2015 FY | -7.72 Million USD | -38.44% |
| 2014 Q1 | -10.53 Thousand USD | 20.57% |
| 2014 Q2 | -16.5 Thousand USD | -56.67% |
| 2014 Q4 | -11.82 Thousand USD | 46.73% |
| 2014 Q3 | -22.19 Thousand USD | -34.46% |
| 2014 FY | -5.57 Million USD | -9632.88% |
| 2013 Q2 | -19.85 Thousand USD | -10.4% |
| 2013 FY | -57.31 Thousand USD | 3.95% |
| 2013 Q4 | -13.26 Thousand USD | 2.88% |
| 2013 Q3 | -13.65 Thousand USD | 31.22% |
| 2013 Q1 | -17.98 Thousand USD | -50.65% |
| 2012 FY | -59.67 Thousand USD | 56.38% |
| 2012 Q4 | -11.94 Thousand USD | -18.46% |
| 2012 Q3 | -10.07 Thousand USD | 48.75% |
| 2012 Q2 | -19.66 Thousand USD | 72.51% |
| 2012 Q1 | -71.53 Thousand USD | -245.34% |
| 2011 Q3 | -26.83 Thousand USD | -51.48% |
| 2011 Q2 | -17.71 Thousand USD | -25.9% |
| 2011 Q4 | -20.71 Thousand USD | 22.81% |
| 2011 Q1 | -14.07 Thousand USD | 5.57% |
| 2011 FY | -136.8 Thousand USD | -126.98% |
| 2010 FY | -60.27 Thousand USD | -2.34% |
| 2010 Q1 | -11.23 Thousand USD | -17.85% |
| 2010 Q2 | -19.06 Thousand USD | -69.7% |
| 2010 Q3 | -12.23 Thousand USD | 35.84% |
| 2010 Q4 | -14.9 Thousand USD | -21.82% |
| 2009 Q4 | -9533.00 USD | 40.03% |
| 2009 Q3 | -15.89 Thousand USD | 28.5% |
| 2009 Q2 | -22.23 Thousand USD | -79.39% |
| 2009 Q1 | -12.39 Thousand USD | 30.71% |
| 2009 FY | -58.89 Thousand USD | -3.01% |
| 2008 Q4 | -17.88 Thousand USD | -60.59% |
| 2008 Q3 | -11.13 Thousand USD | 29.33% |
| 2008 Q2 | -15.75 Thousand USD | -34.66% |
| 2008 Q1 | -11.7 Thousand USD | 17.91% |
| 2008 FY | -57.17 Thousand USD | -16.79% |
| 2007 Q4 | -14.25 Thousand USD | 7.94% |
| 2007 FY | -48.95 Thousand USD | 0.0% |
| 2007 Q3 | -15.48 Thousand USD | -106.21% |
| 2007 Q2 | -7510.00 USD | 0.0% |
| 2006 Q4 | -1905.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 132.902% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -411.339% |
| Embecta Corp. | 70.4 Million USD | 122.506% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 137.764% |
| PainReform Ltd. | -9.34 Million USD | -69.563% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -251.617% |
| SCYNEXIS, Inc. | 67.04 Million USD | 123.633% |
| Journey Medical Corporation | -3.85 Million USD | -311.212% |
| Safety Shot Inc | -15.08 Million USD | -5.045% |
| Alpha Teknova, Inc. | -36.78 Million USD | 56.922% |
| Bright Green Corporation | -13.12 Million USD | -20.692% |
| Procaps Group, S.A. | 42.54 Million USD | 137.245% |
| Alvotech | -551.73 Million USD | 97.128% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 184.371% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -101.321% |
| Cosmos Health Inc. | -18.54 Million USD | 14.554% |
| Dynavax Technologies Corporation | -6.38 Million USD | -147.989% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 92.428% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 88.656% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -251.617% |
| Theratechnologies Inc. | -23.95 Million USD | 33.865% |
| Harrow Health, Inc. | -24.41 Million USD | 35.095% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -227.694% |
| Biofrontera Inc. | -20.13 Million USD | 21.296% |
| DURECT Corporation | -27.62 Million USD | 42.644% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 1303.951% |
| Cronos Group Inc. | -73.96 Million USD | 78.578% |
| OptiNose, Inc. | -35.48 Million USD | 55.348% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 98.419% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 62.454% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 166.249% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 420.404% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 10125.754% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -152.32% |
| Radius Health, Inc. | -25.79 Million USD | 38.568% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -157.08% |
| ProPhase Labs, Inc. | -16.78 Million USD | 5.589% |
| Phibro Animal Health Corporation | 2.41 Million USD | 755.795% |
| Procaps Group S.A. | 42.54 Million USD | 137.245% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -54.155% |
| Viatris Inc. | 54.7 Million USD | 128.965% |
| Rockwell Medical, Inc. | -8.43 Million USD | -87.747% |
| SIGA Technologies, Inc. | 68.06 Million USD | 123.276% |
| Tilray Brands, Inc. | -244.98 Million USD | 93.533% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 231.89% |
| Shineco, Inc. | -22.44 Million USD | 29.422% |
| PetIQ, Inc. | 2.13 Million USD | 843.501% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -268.308% |
| Incannex Healthcare Limited | -18.45 Million USD | 14.167% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 106.345% |
| Alimera Sciences, Inc. | -20.13 Million USD | 21.299% |
| Silver Spike Investment Corp. | 7.34 Million USD | 315.855% |
| Assertio Holdings, Inc. | -331.94 Million USD | 95.227% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -140.326% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -94.091% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 11.481% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 21.006% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 90.115% |
| Hempacco Co., Inc. | -13.12 Million USD | -20.706% |
| Talphera, Inc. | -18.39 Million USD | 13.877% |
| Alvotech | -551.73 Million USD | 97.128% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 144.453% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 104.85% |
| Currenc Group, Inc. | -15.3 Million USD | -3.511% |
| Kamada Ltd. | 8.28 Million USD | 291.26% |
| Indivior PLC | 2 Million USD | 892.2% |
| Evoke Pharma, Inc. | -7.79 Million USD | -103.329% |
| Flora Growth Corp. | -57.03 Million USD | 72.221% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 21.006% |
| Evolus, Inc. | -61.68 Million USD | 74.315% |
| HUTCHMED (China) Limited | 100.78 Million USD | 115.721% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 111.519% |
| Akanda Corp. | -32.27 Million USD | 50.909% |